MA56142B1 - Protéine modifiée séparée vp1 de capside de aav5 - Google Patents
Protéine modifiée séparée vp1 de capside de aav5Info
- Publication number
- MA56142B1 MA56142B1 MA56142A MA56142A MA56142B1 MA 56142 B1 MA56142 B1 MA 56142B1 MA 56142 A MA56142 A MA 56142A MA 56142 A MA56142 A MA 56142A MA 56142 B1 MA56142 B1 MA 56142B1
- Authority
- MA
- Morocco
- Prior art keywords
- aav5
- capsid protein
- capsid
- separate modified
- modified capsid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
- C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention se rapporte au domaine de la thérapie génique et de la biologie moléculaire. L'invention concerne plus précisément une protéine modifiée séparée vp1 de capside de virus adéno-associé de sérotype 5 (aav5), qui comprend une ou plusieurs substitutions d'acide aminé par rapport à la protéine vp1 de capside aav5 de type sauvage qui permettent d'augmenter l'efficacité de la transduction, ainsi qu'un capside et un vecteur à base de celui-ci.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2019126509A RU2751592C2 (ru) | 2019-08-22 | 2019-08-22 | Выделенный модифицированный белок VP1 капсида аденоассоциированного вируса 5 серотипа (AAV5), капсид и вектор на его основе |
PCT/RU2020/000445 WO2021034222A1 (fr) | 2019-08-22 | 2020-08-21 | Protéine modifiée séparée vp1 de capside de aav5 |
Publications (2)
Publication Number | Publication Date |
---|---|
MA56142A1 MA56142A1 (fr) | 2023-05-31 |
MA56142B1 true MA56142B1 (fr) | 2023-09-27 |
Family
ID=74660332
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA56142A MA56142B1 (fr) | 2019-08-22 | 2020-08-21 | Protéine modifiée séparée vp1 de capside de aav5 |
Country Status (19)
Country | Link |
---|---|
US (1) | US20220306696A1 (fr) |
EP (1) | EP4019642A4 (fr) |
JP (1) | JP2022545121A (fr) |
KR (1) | KR20220158674A (fr) |
CN (1) | CN114981444A (fr) |
AR (1) | AR119869A1 (fr) |
AU (1) | AU2020331882A1 (fr) |
BR (1) | BR112022003389A2 (fr) |
CA (1) | CA3148964A1 (fr) |
CO (1) | CO2022001833A2 (fr) |
EC (1) | ECSP22021725A (fr) |
IL (1) | IL290802A (fr) |
JO (1) | JOP20220043A1 (fr) |
MA (1) | MA56142B1 (fr) |
MX (1) | MX2022002184A (fr) |
PE (1) | PE20221254A1 (fr) |
RU (1) | RU2751592C2 (fr) |
TW (1) | TW202120690A (fr) |
WO (1) | WO2021034222A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113121654B (zh) * | 2021-04-19 | 2023-11-17 | 信念医药科技(上海)有限公司 | 腺相关病毒衣壳蛋白及包含其的腺相关病毒载体 |
AR126839A1 (es) * | 2021-08-20 | 2023-11-22 | Llc «Anabion» | Proteína de la cápside vp1 modificada aislada del virus adeno-asociado de serotipo 9 (aav9), cápside y vector basado en esta |
AR126840A1 (es) | 2021-08-20 | 2023-11-22 | Llc «Anabion» | Proteína de la cápside vp1 modificada aislada del virus adeno-asociado de serotipo 5 (aav5), cápside y vector basado en esta |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19827457C1 (de) * | 1998-06-19 | 2000-03-02 | Medigene Ag | Strukturprotein von AAV, seine Herstellung und Verwendung |
AU2002360291A1 (en) * | 2001-12-17 | 2003-06-30 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (aav) serotype 8 sequences |
RS60207B1 (sr) | 2011-04-22 | 2020-06-30 | Univ California | Adeno-povezani virioni virusa sa varijantama kapsida i postupci za njihovu primenu |
IN2014DN08812A (fr) | 2012-04-18 | 2015-05-22 | Philadelphia Children Hospital | |
KR102380265B1 (ko) * | 2013-07-22 | 2022-03-29 | 더 칠드런스 호스피탈 오브 필라델피아 | 변종 aav 및 조성물, 세포, 기관 및 조직으로의 유전자 전이를 위한 방법 및 용도 |
US10081659B2 (en) * | 2015-04-06 | 2018-09-25 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Adeno-associated vectors for enhanced transduction and reduced immunogenicity |
PT3356390T (pt) * | 2015-09-28 | 2021-04-21 | Univ Florida | Métodos e composições para vetores virais que se evadem a anticorpos |
WO2017201121A1 (fr) * | 2016-05-17 | 2017-11-23 | University Of Florida Research Foundation, Inc. | Vaa recombiné pour la thérapie génique des poumons |
-
2019
- 2019-08-22 RU RU2019126509A patent/RU2751592C2/ru active
-
2020
- 2020-08-21 CN CN202080074154.9A patent/CN114981444A/zh active Pending
- 2020-08-21 PE PE2022000294A patent/PE20221254A1/es unknown
- 2020-08-21 MX MX2022002184A patent/MX2022002184A/es unknown
- 2020-08-21 US US17/637,099 patent/US20220306696A1/en active Pending
- 2020-08-21 AU AU2020331882A patent/AU2020331882A1/en active Pending
- 2020-08-21 BR BR112022003389A patent/BR112022003389A2/pt unknown
- 2020-08-21 MA MA56142A patent/MA56142B1/fr unknown
- 2020-08-21 EP EP20855760.3A patent/EP4019642A4/fr active Pending
- 2020-08-21 WO PCT/RU2020/000445 patent/WO2021034222A1/fr unknown
- 2020-08-21 JP JP2022512768A patent/JP2022545121A/ja active Pending
- 2020-08-21 KR KR1020227009552A patent/KR20220158674A/ko active Search and Examination
- 2020-08-21 JO JOP/2022/0043A patent/JOP20220043A1/ar unknown
- 2020-08-21 CA CA3148964A patent/CA3148964A1/fr active Pending
- 2020-08-21 TW TW109128700A patent/TW202120690A/zh unknown
- 2020-08-31 AR ARP200102440A patent/AR119869A1/es unknown
-
2022
- 2022-02-21 CO CONC2022/0001833A patent/CO2022001833A2/es unknown
- 2022-02-22 IL IL290802A patent/IL290802A/en unknown
- 2022-03-21 EC ECSENADI202221725A patent/ECSP22021725A/es unknown
Also Published As
Publication number | Publication date |
---|---|
KR20220158674A (ko) | 2022-12-01 |
US20220306696A1 (en) | 2022-09-29 |
CN114981444A (zh) | 2022-08-30 |
WO2021034222A9 (fr) | 2021-04-22 |
RU2751592C2 (ru) | 2021-07-15 |
MX2022002184A (es) | 2022-05-24 |
AR119869A1 (es) | 2022-01-19 |
JP2022545121A (ja) | 2022-10-25 |
BR112022003389A2 (pt) | 2022-05-17 |
CO2022001833A2 (es) | 2022-08-09 |
RU2019126509A (ru) | 2021-06-04 |
MA56142A1 (fr) | 2023-05-31 |
RU2019126509A3 (fr) | 2021-06-04 |
JOP20220043A1 (ar) | 2023-01-30 |
EP4019642A1 (fr) | 2022-06-29 |
TW202120690A (zh) | 2021-06-01 |
CA3148964A1 (fr) | 2021-02-25 |
ECSP22021725A (es) | 2022-08-31 |
PE20221254A1 (es) | 2022-08-16 |
EP4019642A4 (fr) | 2023-09-06 |
WO2021034222A1 (fr) | 2021-02-25 |
IL290802A (en) | 2022-04-01 |
AU2020331882A1 (en) | 2022-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA56142B1 (fr) | Protéine modifiée séparée vp1 de capside de aav5 | |
MA46230A (fr) | Mutations de protéine d'enveloppe du vih stabilisant la forme trimère | |
MA42073A1 (fr) | Nouveaux peptides et combinaison de peptides destinés à être utilisés dans l'immunothérapie contre divers cancers | |
MA43466A1 (fr) | Traitements du cancer de l'utérus | |
MA40794A1 (fr) | Nouveaux peptides et combinaisons de peptides et d'échafaudages destinés à être utilisés en immunothérapie contre le carcinome hépatocellulaire (chc) et d'autres cancers | |
MA51353B1 (fr) | Sérotype du virus adéno-associé recombinant hybride entre aav9 et aavrh74 possédant un tropisme hépatique réduit | |
EA201991911A1 (ru) | Способы и композиции для переноса генов по сосудистой сети | |
MA40813A1 (fr) | Nouveaux peptides et combinaison de peptides destinés à être utilisés dans l'immunothérapie contre diverses tumeurs | |
MA40713A1 (fr) | Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie du cancer du pancréas et d'autres cancers | |
EA202191418A1 (ru) | Рекомбинантные вирусные векторы и нуклеиновые кислоты для их получения | |
MA49513B1 (fr) | Vecteurs viraux recombinants au tropisme modifié et leurs utilisations pour l'introduction ciblée de matériel génétique dans des cellules humaines | |
MA43618A1 (fr) | Nouveaux peptides, association de peptides en tant que cibles et destinés à être utilisés en immunothérapie contre le cancer de la vésicule biliaire et le cholangiocarcinome et autres cancers | |
MA43477A1 (fr) | Immunothérapie contre le mélanome et d'autres cancers | |
MX2022007005A (es) | Construcciones de iarn y metodos para inhibir la expresion de lpa. | |
BR112021020957A2 (pt) | Capsídeos de vírus adenoassociado (aav) variante para liberação intravítrea | |
EA202190528A1 (ru) | КОМПОЗИЦИИ АГЕНТОВ дцРНК ВИРУСА ГЕПАТИТА B (HBV) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
MX2023012722A (es) | Capsides de aav y usos de las mismas. | |
MA64618A1 (fr) | Protéine modifiée séparée vp1 de capside aav9 | |
MA58655B1 (fr) | Acide nucléique optimisé par codons qui code la protéine smn1 | |
MA64619A1 (fr) | Protéine modifiée séparée vp1 de capside aav5 | |
EA202092335A1 (ru) | Композиции на основе эренумаба и пути их применения | |
EA202092694A1 (ru) | Системы и способы количественного определения и модификации вязкости белков | |
EA202190853A1 (ru) | Связывающие dll3 белки и способы применения | |
MA47687B1 (fr) | Vecteurs de virus adéno-associé de clade f, et leurs utilisations | |
EA202192936A1 (ru) | Варианты капсидов aav для доставки в стекловидное тело |